Literature DB >> 24342889

Collagen crosslinking after radial keratotomy.

Uri Elbaz1, Sonia N Yeung, Setareh Ziai, Alejandro D Lichtinger, Noa Avni Zauberman, Yakov Goldich, Allan R Slomovic, David S Rootman.   

Abstract

PURPOSE: The aim of this study was to report the outcomes of corneal collagen crosslinking (CXL) after previous radial keratotomy (RK) in patients with decreasing visual acuity and/or diurnal visual fluctuations.
METHODS: The charts of all patients who had undergone CXL because of a worsening corrected distance visual acuity (CDVA) and/or diurnal visual fluctuations after RK were reviewed retrospectively. Uncorrected distance visual acuity, CDVA, manifest refraction, and corneal topography were recorded preoperatively and at 1, 3, 6, and 12 months after the procedure.
RESULTS: Nine eyes of 6 patients that had undergone an RK 15 to 23 years before the CXL were included in the study. In 5 patients (8 out of 9 eyes), discontinuation of diurnal visual fluctuation was reported between 6 and 12 months after the CXL. The mean uncorrected distance visual acuities pre and 12 months after the CXL were 0.7 logarithm of the minimum angle of resolution (logMAR) and 0.6 logMAR, respectively (P = 0.3). The mean CDVAs pre and 12 months after the CXL were 0.2 logMAR and 0.1 logMAR (P = 0.5), respectively. The mean average keratometry pre and 12 months after the CXL were 40.1 and 39.1 diopters (P = 0.06), respectively. The mean corneal astigmatism values pre and 12 months after the CXL were 2.3 and 1.9 diopters (P = 0.06), respectively. The mean manifest refraction spherical equivalents (MRSEs) before and 12 months after the CXL were +1.4 and +2.5 (P = 0.1), respectively.
CONCLUSIONS: CXL is a safe and effective method to restore corneal stability in eyes with a history of RK. However, some of the effect that was achieved at the 6-month visit was blunted at the 12-month visit. Therefore, a longer follow-up is necessary to validate these findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24342889     DOI: 10.1097/ICO.0000000000000044

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Refractive correction with multifocal intraocular lenses after radial keratotomy.

Authors:  Bárbara Martín-Escuer; José F Alfonso; Luis Fernández-Vega-Cueto; Alberto Domíngez-Vicent; Robert Montés-Micó
Journal:  Eye (Lond)       Date:  2019-02-15       Impact factor: 3.775

2.  Long-Term Outcomes of Radial Keratotomy, Laser In Situ Keratomileusis, and Astigmatic Keratotomy Performed Consecutively over a Period of 21 Years.

Authors:  Priyanka Chhadva; Florence Cabot; Anat Galor; Sonia H Yoo
Journal:  Case Rep Ophthalmol Med       Date:  2015-03-19

3.  Spectacle Independence after Cataract Extraction in Post-Radial Keratotomy Patients Using Hybrid Monovision with ReSTOR(®) Multifocal and TECNIS(®) Monofocal Intraocular Lenses.

Authors:  Isha Gupta; Zack Oakey; Faisal Ahmed; Balamurali K Ambati
Journal:  Case Rep Ophthalmol       Date:  2014-05-22

4.  Evaluation of Changes in Visual Acuity, Contrast Sensitivity and Aberrations in Patients with Keratoconus after Corneal Collagen Cross-linking.

Authors:  Siamak Zarei-Ghanavati; Hamid Khakshour; Mohammadreza Vejdani; Haleh Ghooshkhanei; Amirhosein Vejdani
Journal:  J Ophthalmic Vis Res       Date:  2017 Jul-Sep

5.  Extended depth of focus lens implantation after radial keratotomy [Letter].

Authors:  Arjun Srirampur
Journal:  Clin Ophthalmol       Date:  2019-08-27

6.  Performing Corneal Collagen Cross-linking after Radial Keratotomy in a Patient with Keratoconus: Case Report.

Authors:  Mehmet Ozgur Cubuk; Kamil Bilgihan
Journal:  Beyoglu Eye J       Date:  2019-12-27

Review 7.  Collagen cross-linking: when and how? A review of the state of the art of the technique and new perspectives.

Authors:  Leonardo Mastropasqua
Journal:  Eye Vis (Lond)       Date:  2015-11-29

Review 8.  Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.

Authors:  Duoduo Wu; Dawn Ka-Ann Lim; Blanche Xiao Hong Lim; Nathan Wong; Farhad Hafezi; Ray Manotosh; Chris Hong Long Lim
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.